TrialJournal of clinical immunology2011

Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency.

Michael Borte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.